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Abstract The aim of this phase II trial was to estimate
the objective response rate (ORR) of two different sched-
ules of ixabepilone [weekly or every 3 weeks (Q3W)]
combined with bevacizumab, relative to a reference arm of
weekly paclitaxel and bevacizumab. Patients with human
epidermal growth factor receptor 2-normal, chemotherapy-
naı¨ve metastatic breast cancer (MBC) were randomized
3:3:2 to ixabepilone 16 mg/m2 weekly plus bevacizumab
10 mg/kg Q2W (Arm A: n = 46); ixabepilone 40 mg/m2
Q3W (reduced to 32 mg/m2 after four cycles of treatment)
plus bevacizumab 15 mg/kg Q3W (Arm B: n = 45); or
paclitaxel 90 mg/m2 weekly plus bevacizumab 10 mg/kg
intravenous infusion Q2W (Arm C: n = 32). Of 123 ran-
domized patients, 122 were treated. All were followed for
C19 months; 5 % of patients remained on study treatment
at the time of this analysis. Grade 3 or 4 neutropenia was
more common in Arm B (60 %) than Arms A (16 %) or C
(22 %); other adverse events were similar. The investiga-
tor-assessed ORR was 48, 71, and 63 % for Arms A, B, and
C, respectively. Median progression-free survival (ran-
domized patients) was 9.6 months in Arm A, 11.9 months
in Arm B, and 13.5 months in Arm C. In conclusion, ix-
abepilone Q3W plus bevacizumab has clinical activity as
first-line therapy for MBC relative to paclitaxel plus bev-
acizumab, but with significantly greater risk of grade 3 or 4
neutropenia. In addition, these data suggest that weekly
dosing of ixabepilone may be less active than Q3W dosing,
but with less neutropenia.
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Introduction
Many improvements have been made in the treatment of
metastatic breast cancer (MBC) over the past 5 years;
however, few regimens have translated into an incremental
gain in overall survival (OS). A number of palliative che-
motherapy options exist, with diverse regimens based on
class of drug, number of agents, dosage, and schedule.
Microtubules are a validated target for anticancer therapy;
natural antitubulin agents such as taxanes are active in the
treatment of breast cancer. However, development of drug
resistance and dose-limiting toxicity are the most critical
limitations of taxane therapy. Therefore, agents with the
ability to overcome resistance without increasing toxicity
are needed.
Vascular endothelial growth factor (VEGF), a key
mediator of angiogenesis [1], is over-expressed in many
tumor types, including primary breast cancer [2, 3], and has
been associated with poor prognosis [4–6]. Bevacizumab is
a recombinant humanized monoclonal antibody that blocks
binding of human VEGF-A to its receptors. In addition to
antiangiogenic effects, bevacizumab may produce clinical
benefit through other mechanisms, including direct action
against tumor cells [7]. Clinical activity of bevacizumab
combinations in advanced breast cancer has been demon-
strated in three large, randomized, phase III trials [8–10];
significant improvements have been observed in both
response rate (RR) and progression-free survival (PFS), but
not OS.
Ixabepilone is a semi-synthetic analog of epothilone B
targeting microtubules, but engineered to overcome tumor
survival pathways [11]. In preclinical tumor models
derived from breast, colon, lung, and kidney cancers,
ixabepilone alone and in combination with several targeted
antiangiogenic agents (bevacizumab, sunitinib, or brivanib)
demonstrated robust synergistic antitumor activity [12],
and the synergistic antitumor effect was greater with
ixabepilone than paclitaxel [12, 13]. In addition, ixabepi-
lone was more effective than paclitaxel at killing endo-
thelial cells expressing P-glycoprotein in vitro, and
inhibiting endothelial cell proliferation and tumor angio-
genesis in vivo [13]. In the clinic, ixabepilone has shown
efficacy as monotherapy in several phase II trials in
patients with MBC [14–16], as well as in combination with
capecitabine in two large, phase III trials focusing on
patients with chemotherapy-resistant disease [17, 18]. Most
trials to date have administered ixabepilone on an every
3 week (Q3W) schedule.
Several clinical trials in patients with advanced disease
have tried to identify the optimum dose and schedule for
administration of paclitaxel and docetaxel. Weekly dosing
of paclitaxel was shown to be superior to Q3W dosing in the
metastatic setting [19], less toxic than weekly docetaxel,
and superior to Q3W paclitaxel or docetaxel in early stage
disease [20]. We hypothesized that weekly dosing of
ixabepilone might improve efficacy and reduce toxicity
compared with Q3W dosing. This clinical trial, CA163-115,
was designed to estimate the RR of weekly or Q3W dosing
of ixabepilone combined with bevacizumab, with reference
treatment of weekly paclitaxel and bevacizumab in patients
with chemotherapy-naı¨ve MBC (NCT00370552).
Methods
Patients
Eligible women with human epidermal growth factor
receptor 2 (HER2)-normal metastatic or locally advanced
breast cancer, previously untreated with chemotherapy for
advanced disease, with at least one measurable lesion, Kar-
nofsky performance status score between 80 and 100 %, and
life expectancy C12 weeks, were enrolled. Patients were
permitted to have received prior chemotherapy only in the
neoadjuvant/adjuvant setting; any number of prior lines of
hormone therapy were allowed.
This trial was conducted in accordance with the Dec-
laration of Helsinki, and in compliance with Good Clinical
Practice and local and national regulatory requirements.
The protocol was approved by the Institutional Review
Board or Independent Ethics Committee at each site before
enrollment; all patients provided written informed consent.
Study design
In this multinational, phase II study, patients were ran-
domized in a 3:3:2 ratio to receive ixabepilone weekly or
Q3W plus bevacizumab, or weekly paclitaxel plus bev-
acizumab. The primary endpoint was estimation of RR by
Response Evaluation Criteria in Solid Tumors (version 1.0)
criteria for each ixabepilone arm relative to the paclitaxel
arm. Secondary endpoints included PFS (defined as the
time from randomization to disease progression or death),
week 24 PFS rate, time to response, duration of response,
OS, and safety. Response and progression were determined
by the local investigator. Randomization was stratified by
disease-free interval from initial diagnosis to first recur-
rence (B24 or [24 months), prior taxane therapy (yes or
no), and investigative site. Patients initially diagnosed with
metastatic disease (or locally advanced disease not ame-
nable to surgery) were included in the[24 month disease-
free interval.
For the two ixabepilone experimental arms, patients
received either ixabepilone 16 mg/m2 as a 1-h intravenous
(IV) continuous infusion on days 1, 8, and 15 in a 28-day
cycle, along with bevacizumab as a 10 mg/kg IV infusion
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every 2 weeks (Q2W; Arm A); or ixabepilone 40 mg/m2,
as a 3-h IV infusion on day 1 of a 21-day cycle, along with
bevacizumab as a 15 mg/kg IV infusion Q3W (Arm B).
After four cycles of treatment on Arm B, all patients
remaining on the 40 mg/m2 dose had their ixabepilone
dose reduced to 32 mg/m2 (maintenance). For the reference
treatment (Arm C), patients received paclitaxel 90 mg/m2
as a 1-h IV infusion on days 1, 8, and 15 of a 28-day cycle,
along with bevacizumab administered as a 10 mg/kg IV
infusion Q2W.
Treatment for all arms was continued until disease pro-
gression or unacceptable toxicity. All patients who received
the study drug were evaluated for safety; adverse events (AEs)
were assessed according to National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (version 3.0).
Statistical analysis
At least 45 patients in each of the experimental arms were
required to achieve the maximum width of the exact two-
sided 95 % confidence intervals (CIs) for the RRs in these
arms to be 31 %, when the corresponding RR was to be
30–50 %. This was a randomized, non-comparative trial.
The objective was to estimate endpoints in the three dosing
arms, and formal statistical comparisons were not planned
due to limitations in sample size.
The primary endpoint, objective RR (ORR), was defined
for each arm as the number of patients with best tumor
response including complete response (CR) or partial
response (PR), divided by the number of randomized
patients in the arm. Tumor response analysis consisted of
point estimates of the RR and two-sided exact 95 % CIs
(Clopper–Pearson method) for each treatment arm. The
analyses of PFS and OS were conducted on all randomized
patients, and estimated using the Kaplan–Meier method.
The two-sided 95 % CIs for the median PFS were reported
for each treatment arm. Additional analyses on estimation
of time to response and response duration were conducted
on response-evaluable patients. The Kaplan–Meier method
was used to estimate duration of response, and descriptive
statistics (median, minimum, and maximum) were used to
summarize time to response for the responders in each arm.
Tumor assessments were performed every 8 weeks ± 5
working days until disease progression during the first
12 months from randomization. Thereafter, patients were
assessed for tumor response every 3 months until disease
progression was documented.
The safety profile of the combination of ixabepilone/pac-
litaxel and bevacizumab was assessed through summaries of
AEs, serious AEs (SAEs), deaths, AEs leading to discontin-
uation, and laboratory abnormalities in hematology, liver
function, and renal parameters for all treated patients.
Results
Patients
A total of 123 patients with metastatic or locally advanced
breast cancer were randomized to receive either ixabepi-
lone in Arm A (n = 46) or Arm B (n = 45), or paclitaxel
in Arm C (n = 32), plus bevacizumab, at 23 sites across
five countries over 12 months. A total of 122 patients were
treated: one patient in Arm A was not treated (Fig. 1). The
majority of demographic characteristics were balanced
between arms (Table 1) except for sites of metastases;
fewer patients had liver and/or lung metastasis in Arm C
compared with patients in Arms A and B.
Exposure
Patients received a median of 6.0 cycles (range 1–14) of
chemotherapy in Arm A, 7.0 (range 1–28) in Arm B, and
6.5 (range 2–21) in Arm C. The median number of courses
of bevacizumab received by each patient was 6.0 (range
1–24) in Arm A, 10.5 (range 1–37) in Arm B, and 10.5
(range 2–22) in Arm C. Of the 117 patients who had at
least two cycles of ixabepilone or paclitaxel chemotherapy,
48 patients (Arm A: 43 %; Arm B: 40 %; Arm C: 41 %)
had at least one dose reduction of chemotherapy; of these,
peripheral neuropathy was the most common reason for the
first dose reduction in all three arms (Arm A: n = 10,
24 %; Arm B: n = 12, 28 %; Arm C: n = 6, 19 %). In
Arms A, B and C, 14, 15, and 17 % of patients experienced
delay in receiving chemotherapy, and 14, 15, and 16 % of
patients experienced delays in receiving bevacizumab,
respectively. Dose intensity for ixabepilone was similar
between the weekly and Q3W arms (11.5 and 11.2 mg/m2/
week), but due to less delivered cycles the cumulative dose
was lower on the weekly versus the Q3W arm (231 vs.
257 mg/m2). Ninety-five percent of the patients in the
study discontinued treatment at the time of this analysis
(Arm A: 98 %; Arm B: 93 %; Arm C 94 %); of these,
50 % discontinued due to disease progression (Arm A:
51 %; Arm B: 51 %; Arm C: 47 %). Eight patients (Arm
A: n = 3, 7 %; Arm B: n = 2, 4 %; Arm C: n = 3, 9 %)
discontinued bevacizumab and continued treatment on
ixabepilone or paclitaxel alone.
Safety
Most patients had treatment-related AEs (Table 2). Treat-
ment-related SAEs were reported in 16 % of patients each
in Arms A and C, and 20 % of patients in Arm B. The most
common drug-related SAEs, presented as the number of
events over the total treated patients in each arm, were
neutropenia (7 % of patients in Arm B), leukopenia and
Breast Cancer Res Treat (2013) 139:411–419 413
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hypersensitivity (each, 4 % of patients in Arm B), pyrexia
(2 % of patients each in Arms A and B, and 3 % of patients
in Arm C), and hypertension (2 % of patients each in Arms
A and B). Among the non-hematologic AEs, peripheral
neuropathy was most common. Rates were similar between
Arms A, B, and C (all grades: 76, 80, and 81 %; grade 3:
18, 24, and 25 %); no grade 4 events were reported. Grade
3 or 4 neutropenia was more common in Arm B (60 %)
than in Arm A (16 %) or Arm C (22 %), and febrile neu-
tropenia was only reported for one patient in Arm B.
Pyrexia was mostly grade 1 and more common in Arm C
(Arm A: 7 %; Arm B: 4 %; Arm C: 19 %); the rate of all-
grade hypersensitivity was similar across the three treat-
ment arms.
Fifty-five percent of patients (Arm A: 53 %; Arm B:
51 %; Arm C: 63 %) in the study discontinued treatment of
either one or both study drug combinations due to treat-
ment-related AEs. Grade 3 peripheral sensory neuropathy
led to the discontinuation of treatment in 19 patients (Arm
A: 13.3 %; Arm B: 15.6 %; Arm C: 18.8 %). A total of 32
(26 %) randomized patients (Arm A: 26 %; Arm B: 33 %;
Arm C: 16 %) died due to their underlying disease. None
died within 30 days of the last dosing date and there were
no drug-related deaths.
Primary efficacy measure (ORR)
The ORR (assessed by investigators among all randomized
patients) was 48 % (22/46; 95 % CI 32.9–63.1) for Arm A,
71 % (32/45; 95 % CI 55.7–83.6) for Arm B, and 63 %
(20/32; 95 % CI 43.7–78.9) for Arm C (Table 3). Two
patients (4 %) each in Arms A and B, and four patients
(13 %) in Arm C, had a CR; 20 patients (43 %) in Arm A,
30 patients (67 %) in Arm B, and 16 patients (50 %) in
Arm C had a PR; 18 patients (39 %) in Arm A, nine
patients (20 %) in Arm B, and 11 patients (34 %) in Arm C
had stable disease. Five patients (11 %) in Arm A, three
patients (7 %) in Arm B, and no patients in Arm C, had
progressive disease as the best response.
A sensitivity analysis (defined retrospectively) comput-
ing ORR by excluding those patients assumed as non-
responders for this analysis, who received non-protocol
therapy (any systemic therapy, surgery, or radiation) prior
Discontinued treatment* 
• Disease progression (n = 23)
• Study drug toxicity (n = 11)
• Patient request (n = 2)
• Maximum clinical benefit (n = 3)
• AE unrelated to study drug (n = 2)
Arm A: Ixabepilone (QW) + 
bevacizumab 
• Received (n = 45)
• Never treated (n = 1)
Efficacy:
Randomized patients (n = 46)
Safety:
Treated patients (n = 45)
Discontinued treatment* 
• Disease progression (n = 23)
• Study drug toxicity ( n = 8)
• Patient request (n = 0)
• Maximum clinical benefit (n = 5)
• AE unrelated to study drug (n = 2)
Arm B: Ixabepilone (Q3W) + 
bevacizumab 
• Received (n = 45)
Efficacy:
Randomized patients (n = 45)
Safety:
Treated patients (n = 45)
Discontinued treatment* 
• Disease progression (n = 15)
• Study drug toxicity (n = 6)
• Patient request (n = 1)
• Maximum clinical benefit (n = 5)
• AE unrelated to study drug (n = 2)
Arm C: Paclitaxel +
 bevacizumab 
• Received (n = 32)
Efficacy:
Randomized patients (n = 32)
Safety:
Treated patients (n = 32)
Allocation
Follow-up
Analysis
Enrolled
(N = 136)
Randomized 3:3:2
(n = 123)
*Key reasons for discontinuation
Fig. 1 CONSORT diagram. Asterisks key reasons for discontinuation, AE adverse event, Q3W every 3 weeks, QW every week
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to achieving a CR or PR, resulted in an ORR of 46 % in
Arm A, 69 % in Arm B, and 59 % in Arm C.
Other outcome measures
At the time of the final analysis, 102 randomized
patients (83 %) had progressed or died, giving an estimated
median PFS of 9.6 months (95 % CI 6.1–11.7) for patients in
Arm A, 11.9 months (95 % CI 8.7–14.7) for patients in Arm
B, and 13.5 months (95 % CI 10.0–18.2) for patients in Arm C
(Table 4; Fig. 2). A sensitivity analysis of PFS censoring
patients who received non-protocol therapy prior to disease
progression or last tumor assessment (in case no progression
was observed) at the earliest start date of this subsequent
therapy, showed a median PFS of 9.7 months in Arm A,
13.8 months in Arm B, and 13.7 months in Arm C. At week
24, the estimated PFS rates were 75 % in Arm A, 86 % in Arm
B, and 94 % in Arm C (Table 4). Similar results were also
reported for the estimated week 24 PFS rates with censoring
for non-protocol therapy administered prior to progressive
disease: 82 % in Arm A, 88 % in Arm B, and 94 % in Arm C.
The 1-year OS rates were 91 % in Arm A, 89 % in Arm
B, and 91 % in Arm C (Table 4); however, the median OS
could not be determined based on the number of deaths at
the time of the final analysis (12 in Arm A, 15 in Arm B,
and five in Arm C). Median time to response (for ran-
domized patients with a response of CR or PR) was similar
among the three study arms (Table 4; Arm A: 8.2 weeks;
Arm B: 8.3 weeks; Arm C: 8.1 weeks). Median duration of
response for randomized patients with a response of CR or
PR was 10.1 months in Arm A, 10.3 months in Arm B, and
13.1 months in Arm C (Table 4).
Discussion
Despite recent advances in treatment, MBC remains
incurable with a median survival of just over 2 years [9].
Table 1 Baseline patient demographics and disease characteristics
Characteristic Ixabepilone ? bevacizumab Paclitaxel ? bevacizumab
Arm A (n = 46) Arm B (n = 45) Arm C (n = 32)
Age, year
Median (range) 60 (27–80) 59 (37–83) 59 (37–75)
Karnofsky performance status, n (%)
90–100 34 (73.9) 30 (66.7) 22 (68.8)
70–80 10 (21.7) 15 (33.3) 10 (31.2)
\70 1 (2.2) – –
Not reported 1 (2.2) – –
Hormone receptor status, n (%)
ER-positive 37 (80.4) 35 (77.8)a 27 (84.4)
ER-negative 8 (17.4) 9 (20.0)a 5 (15.6)
HER2-negative 45 (97.8) 45 (100.0) 32 (100.0)
ER-negative, progesterone receptor-negative, HER2-negative 8 (17.4) 9 (20.0) 5 (15.6)
Site of visceral disease, n (%)
Liver 22 (47.8) 21 (46.7) 9 (28.1)
Liver and/or lung 37 (80.4) 28 (62.2) 18 (56.3)
Median time from initial diagnosis to randomization, months 38.5 37.8 55.2
Number of disease lesions, n (%)
C3 24 (52.1) 19 (42.2) 14 (43.7)
Prior chemotherapy regimens—neoadjuvant/adjuvant setting, n (%)
0 23 (50.0) 22 (48.9) 14 (43.8)
1 21 (45.7) 22 (48.9) 13 (40.6)
2 2 (4.3) 1 (2.2) 5 (15.6)
Prior therapy, n (%)
Any chemotherapy 23 (50) 23 (51) 18 (56.3)
Any hormonal therapy 25 (54.3) 25 (55.6) 19 (59.4)
Taxanes 7 (15.2) 6 (13.3) 6 (18.8)
ER estrogen-receptor, HER2 human epidermal growth factor receptor 2
a The ER status of one patient in Arm B was unknown
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For patients with newly diagnosed, hormone resistant
HER2-normal metastatic disease, taxanes remain a current
standard of care option. Several clinical trials have tried to
identify the optimum dose and schedule for administration
of paclitaxel and docetaxel. Preclinical and clinical evi-
dence suggested that docetaxel was more effective than
Q3W paclitaxel, and that weekly paclitaxel was more
effective than dosing Q3W [19, 21]. In the large, ran-
domized Cancer and Leukemia Group B (CALGB) 9840
trial, assessing more than 700 patients by preplanned
analysis, weekly scheduling of paclitaxel improved RR (40
vs. 28 %; P = 0.0017) and median time to disease pro-
gression (9 vs. 5 months; P = 0.0008) compared with
Q3W [19]. In the adjuvant setting, the Eastern Cooperative
Oncology Group (ECOG) 1199 trial further supported this
schedule of paclitaxel as efficacious and tolerable [20].
Exposure to lower, more frequent doses of paclitaxel may
potentially exploit antiangiogenic effects; one rationale for
combining weekly paclitaxel with bevacizumab in the
metastatic setting (ECOG 2100) [9, 22]. Despite the recent
withdrawal of accelerated approval of bevacizumab for the
treatment of MBC, the combination with weekly paclitaxel
remains the most impressive data for bevacizumab to date,
with an almost doubling of PFS compared with paclitaxel
alone.
In this open-label, randomized, phase II trial, the com-
bination of ixabepilone and bevacizumab was found to be
safe and active as first-line therapy in patients with HER2-
normal MBC. Imbalances in baseline characteristics may
have favored the paclitaxel plus bevacizumab arm (Arm
C); Arm C had fewer patients with liver metastasis, and
patients had a longer time from initial diagnosis to ran-
domization. An ORR of 71 % in the Q3W ixabepilone arm
suggests similar clinical activity for this combination rel-
ative to paclitaxel and bevacizumab (63 %), and median
PFS was similar at 13.8 and 13.7 months for Arms B and C
when adjusted for non-protocol treatment. Interestingly, a
similar ORR of 49.2 % and a median PFS of 11.8 months
Table 2 Most frequent drug-related AEs (C20 % in any treatment group for all grades): treated patients
AEs Ixabepilone ? bevacizumab Paclitaxel ? bevacizumab
Arm A (n = 46) Arm B (n = 45) Arm C (n = 32)
Any Grade 3 or 4 Any Grade 3 or 4 Any Grade 3 or 4
Non-hematologic abnormality, n (%)
Peripheral neuropathy 34 (75.6) 8 (17.8)a 36 (80.0) 11 (24.4)a 26 (81.3) 8 (25.0)a
Epistaxis 22 (48.9) 0 16 (35.6) 0 19 (59.4) 0
Alopecia 17 (37.8) 0 22 (48.9) 0 17 (53.1) 0
Diarrhea 21 (46.7) 5 (11.1) 11 (24.4) 0 17 (53.1) 1 (3.1)
Nausea 17 (37.8) 1 (2.2) 12 (26.7) 1 (2.2) 11 (34.4) 0
Hypertension 12 (26.7) 1 (2.2) 20 (44.4) 2 (4.4) 7 (21.9) 2 (6.3)
Asthenia 14 (31.1) 1 (2.2) 16 (35.6) 6 (13.3) 9 (28.1) 0
Headache 15 (33.3) 1 (2.2) 9 (20.0) 0 11 (34.4) 0
Nail disorder 10 (22.2) 0 8 (17.8) 0 15 (46.9) 1 (3.1)
Fatigue 13 (28.9) 1 (2.2) 9 (20.0) 2 (4.4) 10 (31.3) 0
Vomiting 13 (28.9) 1 (2.2) 6 (13.3) 1 (2.2) 10 (31.3) 0
Constipation 13 (28.9) 0 9 (20.0) 0 6 (18.8) 0
Mucosal inflammation 7 (15.6) 0 10 (22.2) 1 (2.2) 8 (25.0) 0
Myalgia 11 (24.4) 2 (4.4) 11 (24.4) 0 2 (6.3) 0
Dysgeusia 9 (20.0) 0 8 (17.8) 0 4 (12.5) 0
Stomatitis 4 (8.9) 0 10 (22.2) 2 (4.4) 5 (15.6) 0
Decreased appetite 9 (20.0) 0 9 (20.0) 1 (2.2) 1 (3.1) 0
Rash 7 (15.6) 0 4 (8.9) 0 8 (25.0) 0
Hematologic abnormality, n (%)
Leukopenia 28 (62.2) 3 (6.7) 42 (93.3) 18 (40.0) 26 (81.3) 3 (9.4)
Neutropenia 26 (57.8) 7 (15.6) 41 (91.1) 27 (60.0) 26 (81.3) 7 (21.9)
Anemia 26 (57.8) 2 (4.4) 27 (60.0) 3 (6.7) 22 (68.8) 2 (6.3)
Thrombocytopenia 7 (15.6) 2 (4.4) 17 (37.8) 1 (2.2) 3 (9.4) 0
AEs adverse events
a No grade 4 event was reported
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were reported in ECOG 2100 [9]. The CIRG/TORI 010
randomized phase II study of first-line chemotherapy for
MBC (weekly paclitaxel vs. weekly paclitaxel plus bev-
acizumab vs. weekly paclitaxel plus motesanib) also
reported a median PFS of 11.5 months and an ORR rate of
52 % for the paclitaxel/bevacizumab arm (n = 97) [23].
Both the ORR (48 %) and PFS (9.6 months) for the weekly
ixabepilone arm were inferior to both Q3W ixabepilone
and weekly paclitaxel, although median dose intensity was
similar, suggesting that the improved efficacy of the Q3W
schedule is due to a higher delivered dose of ixabepilone at
each infusion. Estimation of median OS was not possible in
the current trial, but 1-year OS rates were 91, 89, and 91 %
for Arms A, B, and C, respectively.
The safety data from this study demonstrated that ix-
abepilone plus bevacizumab (Arms A and B) was reason-
ably well tolerated, with comparable discontinuation rates
for toxicity to paclitaxel plus bevacizumab (Arm C). In
particular, the incidence of grade 3 peripheral sensory
neuropathy (no grade 4 reported) was similar among the
three study arms. However, grade 3 or 4 neutropenia was
more common in Arm B (60 %) than Arm A (16 %) or
Arm C (22 %), but was not associated with an increase in
rates of febrile neutropenia (reported in one patient in Arm
B), consistent with that observed in monotherapy studies
with this dose and schedule of ixabepilone. Bevacizumab-
associated toxicities (grade 3 or 4 hypertension and pro-
teinuria) were within the expected range in all three arms
relative to phase III studies of chemotherapy plus bev-
acizumab in first-line MBC [8–10]. The addition of bev-
acizumab had no meaningful impact on the frequency or
severity of ixabepilone or paclitaxel-related toxicities.
These data demonstrated acceptable efficacy and safety
with weekly ixabepilone compared with Q3W dosing, and
supported the design and dosing of the phase III coopera-
tive group trial CALGB 40502, comparing weekly ixab-
epilone or weekly nab-paclitaxel with weekly paclitaxel,
given in combination with bevacizumab (NCT00785291)
Table 3 Objective tumor
responses in randomized
patients: primary endpoint
CI confidence interval,
CR complete response,
ORR objective response rate,
PR partial response
Ixabepilone ? bevacizumab Paclitaxel ? bevacizumab
Arm A (n = 46) Arm B (n = 45) Arm C (n = 32)
ORR, n (%) 22 (47.8) 32 (71.1) 20 (62.5)
95 % CI 32.9–63.1 55.7–83.6 43.7–78.9
CR, n (%) 2 (4) 2 (4) 4 (13)
PR, n (%) 20 (43) 30 (67) 16 (50)
Stable disease, n (%) 18 (39) 9 (20) 11 (34)
Progressive disease, n (%) 5 (11) 3 (7) 0 (0)
Not determined, n (%) 1 (2) 1 (2) 1 (3)
Table 4 Summary of secondary efficacy endpoints: randomized patients
Ixabepilone ? bevacizumab Paclitaxel ? bevacizumab
Arm A (n = 46) Arm B (n = 45) Arm C (n = 32)
PFS
No. of events/no. of patients 40/46 36/45 26/32
Median, months (95 % CI) 9.7 (6.1–11.6) 11.9 (8.7–14.7) 13.5 (10.0–18.2)
Week 24 PFS
Rate, % (95 % CI) 75 (62.37–87.87) 86 (75.72–96.42) 94 (84.90–100.0)
Deaths
No. of events/no. of patients 12/46 15/45 5/32
Rate, % 26 33 16
OS
1-year rate, % (95 % CI) 91 (82.69–99.42) 89 (79.71–98.07) 91 (80.53–100.0)
Time to response (n = 22) (n = 32) (n = 20)
Median, weeks (range) 8.2 (6.1–67.0) 8.3 (5.3–37.9) 8.1 (7.0–32.0)
Duration of response (n = 22) (n = 32) (n = 20)
Median, months (95 % CI) 10.1 (7.3–14.5) 10.3 (9.0–14.3) 13.1 (9.2–21.7)
CI confidence interval, OS overall survival, PFS progression-free survival
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[24]. While no definitive conclusions can be made from
this trial about the relative differences in efficacy between
the two ixabepilone arms, these data suggest that the Q3W
schedule of ixabepilone plus bevacizumab (Arm B) might
be more active than the weekly schedule (Arm A). Indeed,
the results of CALGB 40502 confirmed inferior efficacy
with weekly ixabepilone compared with weekly paclitaxel
[24]. Q3W ixabepilone was associated with a greater rate
of neutropenia but not more febrile neutropenia; otherwise
toxicity was manageable and similar between the three
arms. Notably, the toxicity associated with Q3W ixabepi-
lone was more favorable than that reported in heavily pre-
treated patients, with rates of grade 3 peripheral neuropathy
similar to weekly paclitaxel. These data, taken in combi-
nation with the recently reported data from CALGB 40502,
suggest that ixabepilone should be administered in the
Q3W schedule. Weekly paclitaxel may be as efficacious in
the first-line setting, with less neutropenia.
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